(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 31.43% in 21 sessions from €0.7 to €0.92 at 14:52 EST on Thursday, after two consecutive sessions in a row of losses. CAC 40 is rising 0.55% to €7,137.96, after three successive sessions in a row of losses.
ERYTECH PHARMA’s last close was €0.88, 40.77% under its 52-week high of €1.48.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.98%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be overbought (>=80).
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.91%, a positive 0.72%, and a positive 3.65%.
ERYTECH PHARMA’s highest amplitude of average volatility was 2.08% (last week), 4.13% (last month), and 3.65% (last quarter).
Volume
Today’s last reported volume for ERYTECH PHARMA is 60397 which is 77.67% below its average volume of 263186.
Moving Average
ERYTECH PHARMA’s value is above its 50-day moving average of €0.85 and way higher than its 200-day moving average of €0.79.
More news about ERYTECH PHARMA (ERYP.PA).
